OCGN — Ocugen, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1372299 ·
Last close
$0.76
Market Cap
$256.75M
52W High
$2.72
52W Low
$0.69
ADV30
7,414,813
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 1,951,000 | — | -17,753,000 | -3,598,000 | 108,061,000 | 24,632,000 | 125,742,000 |
| Jun 2026 | 1,488,000 | — | -16,444,000 | -24,877,000 | 124,206,000 | 100,051,000 | 140,762,000 |
| Mar 2026 | 1,533,000 | — | -17,839,000 | -19,177,000 | 56,905,000 | 31,855,000 | 51,100,000 |
| Dec 2025 | -193,000 | — | -16,995,000 | -17,706,000 | 43,516,000 | 18,571,000 | 55,682,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-63,692,000
Investing CF
$-59,836,000
Financing CF
$115,515,000
CapEx
$-211,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.20
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-455,719,000
Inventory
—
Receivables
$536,000
ST Investments
$59,625,000
EBIT TTM
$-55,140,000
Pretax Income TTM
$-65,358,000
Interest Exp TTM
$10,218,000
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,780,000
EBITDA
$-67,703,000
Free Cash Flow
$-21,493,000
Enterprise Value
$318,163,616
Total Cash
$84,257,000
Total Debt
$88,562,000
Shares Out
339,306,603
Trailing EPS
$-0.20
Book Value
$-0.05
ROE
-660.0%
ROA
-52.1%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,413,000 | -62,916,000 | -67,846,000 | 43,516,000 | 55,682,000 | -12,166,000 | -56,964,000 |
| Dec 2024 | 4,055,000 | -54,757,000 | -54,054,000 | 82,442,000 | 52,810,000 | 29,632,000 | -42,142,000 |
| Dec 2023 | 6,036,000 | -65,531,000 | -63,078,000 | 64,547,000 | 23,983,000 | 40,564,000 | -62,054,000 |
| Dec 2022 | 2,488,000 | -89,071,000 | -86,804,000 | 108,632,000 | 34,651,000 | 73,981,000 | -60,079,000 |
TTM Snapshot
Revenues TTM
$4,580,000
NetIncome TTM
$-81,811,000
OpCashFlow TTM
—
Assets (Latest)
$124,206,000
Forward EPS
$-0.25
Max Pain — expiry 2027-04-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $0.50 · spot: $0.74 · call volume: 311 · put volume: 52
Expected Move to 2027-04-16:
±$0.44
(59.54%) —
implied range
$0.30 –
$1.18
· ATM straddle on $0.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ALLO | Allogene Therapeutics, Inc. | $257.08M | $0.74 | — |
| IPSC | Century Therapeutics, Inc. | $248.79M | $1.37 | — |
| SABS | SAB Biotherapeutics, Inc. | $265.76M | $2.95 | — |
| PLX | Protalix BioTherapeutics, Inc. | $242.84M | $2.88 | — |
| TRXB | TRex Bio, Inc. | $274.46M | $10.00 | — |
News headlines (Yahoo Finance, 1h cache)
Ocugen Eyes 2027 Trial Results and FDA Filing for Lead Gene Therapy
2026-11-12 18:14 · Yahoo
Ocugen and Celairis Therapeutics Enter into Exclusive License Agreement for OCU400 in Australia, New Zealand, and ASEAN
2026-11-10 12:00 · Yahoo
Ocugen's Q3 Earnings Match Estimates, Revenues Beat, Stock Rises
2026-11-05 12:40 · Yahoo
Ocugen Inc (OCGN) Q3 2026 Earnings Call Highlights: Three Gene Therapy Programs Reach Phase 3 ...
2026-11-04 21:11 · Yahoo
Ocugen Q3 Earnings Call Highlights
2026-11-04 19:14 · Yahoo
Ocugen, Inc. Q3 2026 Earnings Call Summary
2026-11-04 18:34 · Yahoo
Ocugen (OCGN) Q3 2026 Earnings Call Transcript
2026-11-04 17:30 · Yahoo
Ocugen (OCGN) Reports Q3 Loss, Tops Revenue Estimates
2026-11-04 12:55 · Yahoo
Ocugen: Q3 Earnings Snapshot
2026-11-04 12:14 · Yahoo
Ocugen Provides Business Update with Third Quarter 2026 Financial Results
2026-11-04 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.